Literature DB >> 2693627

Imaging of irradiated brain tumours. Value of magnetic resonance imaging.

J C Castel, J M Caillé.   

Abstract

Until recently, computerized tomography (CT) was the most sensitive and reliable imaging method to follow up patients with an irradiated brain tumour, but it is difficult or impossible with CT to differentiate between radionecrosis, residual tumour or recurrent tumour. Magnetic resonance imaging (MRI) has become the most sensitive examination. It ensures optimal focusing of radiography, thereby increasing its effectiveness and reducing its complications. In one-third of the cases studied, MRI has shown pathological signals that were invisible at CT, making for a better adjustment of treatment and a more accurate diagnosis. As regards specificity, MRI does not seem to provide criteria that would enable a radiation lesion to be distinguished from a tumoral recurrence. However, we found that certain signs may contribute to the aetiological diagnosis: a perilesional high-intensity signal extending to the grey matter and/or the corpus callosum is in favour of a recurrent tumour; a high-intensity signal on T1- and T2-weighted sequences and a disproportionally moderate mass syndrome are in favour of a radionecrosis; a post-irradiation leucoencephalopathy sparing the grey matter and the corpus callosum is in favour of a remission. Injecting a gadolinium complex always gives a better distinction between oedema, tumour and necrosis, it may also improve MRI sensitivity and sensitivity in some cases, and it reduces the time taken by the examination. MRI is now the reference morphological examination; its specificity can be further increased by positron emission tomography and assays of polyamines in red blood cells.

Entities:  

Mesh:

Year:  1989        PMID: 2693627

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  8 in total

1.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.

Authors:  Jun-Ling Xu; Yong-Li Li; Jian-Min Lian; She-wei Dou; Feng-Shan Yan; Hui Wu; Da-peng Shi
Journal:  Neuroradiology       Date:  2010-06-23       Impact factor: 2.804

3.  Asymptomatic cystic changes in the brain of children after cranial irradiation: frequency, latency, and relationship to age.

Authors:  Mika Kitajima; Toshinori Hirai; Natsuki Maruyama; Masayuki Yamura; Yoshiko Hayashida; Yuji Baba; Ryuji Murakami; Yasuyuki Yamashita; Yukunori Korogi; Hideo Nakamura; Jun-Ichi Kuratsu
Journal:  Neuroradiology       Date:  2007-01-23       Impact factor: 2.804

4.  Radiotherapy response of cerebral metastases quantified by serial MR imaging.

Authors:  E J Zijlstra; M J Taphoorn; F Barkhof; F G Hoogenraad; J J Heimans; J Valk
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?

Authors:  Amanda J Walker; Jake Ruzevick; Ashkan A Malayeri; Daniele Rigamonti; Michael Lim; Kristin J Redmond; Lawrence Kleinberg
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404

6.  Radiation necrosis masquerading as late tumor recurrence: 14 years after combined fractionated stereotactic radiosurgery and conventional radiation therapy.

Authors:  James H Brashears; Kristi Vissage; Joseph Jenrette
Journal:  Radiol Case Rep       Date:  2015-12-07

Review 7.  Temporal Lobe Necrosis Following Radiotherapy in Nasopharyngeal Carcinoma: New Insight Into the Management.

Authors:  Xin Zhou; Peiyao Liu; Xiaoshen Wang
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

Review 8.  Treatment of Radiation-Induced Brain Necrosis.

Authors:  Xiaojing Yang; Hanru Ren; Jie Fu
Journal:  Oxid Med Cell Longev       Date:  2021-12-24       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.